The RSV therapy market is characterized by a large and growing population of people at risk of infection every year. At greatest risk are infants and the elderly. No interventions are approved for adults, contributing to the substantial unmet need for antivirals and vaccines. Several companies are developing therapeutic antivirals and prophylactic vaccines and antibodies for RSV. The anticipated launch of these agents is expected to transform the RSV space.

Table of contents

  • Respiratory Syncytial Virus - Landscape & Forecast - Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Findings
        • Respiratory Syncytial Virus Market Parameters and Forecast
        • Respiratory Syncytial Virus SWOT Analysis
        • Actionable Recommendations in Respiratory Syncytial Virus
    • Commercial Outlook
      • Market Outlook
        • Key Findings
        • Market Overview
        • Respiratory Syncytial Virus Market Landscape
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Respiratory Syncytial Virus?
        • What Factors Are Constraining the Market for Respiratory Syncytial Virus?
    • Forecast
      • Forecast Sales of Key Therapies in Respiratory Syncytial Virus
    • Etiology and Pathophysiology
      • Etiology
        • Risk Factors
      • Pathophysiology
        • Clinical Presentation and Symptomology
          • Symptoms of RSV Infection
          • Typical RSV Symptoms
        • Key Pathways and Drug Targets
          • Respiratory Syncytial Virus Structure
      • Epidemiology Overview
        • Introduction
          • Key Findings
          • Expert Insight
          • Key Findings
          • Events of Respiratory Syncytial Virus per 1,000 Among People of All Ages in 2015 and 2025
          • Key Findings
          • Relative Sizes of the Contributing Factors to the Trend in Events of Respiratory Syncytial Virus over the Forecast Period
          • Key Findings
          • Analysis of the Events of Respiratory Syncytial Virus in 2015 by Age-Group
        • Epidemiology Populations
          • Disease Definition
          • Methods
          • Sources Used for Diagnosed Events of Respiratory Syncytial Viral: Inpatient Setting
          • Diagnosed Events of Respiratory Syncytial Virus: Inpatient Setting, 2015-2025 (thousands)
          • Disease Definition
          • Methods
          • Sources Used for Diagnosed Events of Respiratory Syncytial Virus - Outpatient Setting
          • Diagnosed Events of Respiratory Syncytial Virus: Outpatient Setting, 2015-2025 (thousands)
          • Disease Definition
          • Methods
          • Sources Used for Pediatric Patients, by Risk Group
          • Pediatric Patients by Risk Group, 2015-2025 (in thousands)
          • Disease Definition
          • Methods
          • Sources Used for the Number of Singleton Pregnancies
          • Number of Singleton Pregnancies, 2015-2025 (thousands)
          • Disease Definition
          • Methods
          • Sources Used for Gestational Age
          • Number of Births by Gestational Age, 2015-2025 (thousands)
      • Current Treatment Overview
        • Introduction
          • Key Findings
          • Expert Insight
          • Treatment Overview
        • Diagnosis
          • Expert Insight
          • Treatment Providers and Referral Patterns
          • Expert Insight on Diagnosis of Respiratory Syncytial Virus
        • Treatment Goals
          • Key End Points Used in Clinical Trials for Respiratory Syncytial Virus
          • Key Physician Insights on Clinical End Points
        • Key Current Therapies
          • Overview
          • Market Events Impacting the Use of Key Current Therapies in Respiratory Syncytial Virus
          • Clinical Trial Outcomes for Palivizumab
          • Clinical Analysis of Palivizumab for the Treatment of Respiratory Syncytial Virus
          • Advantages and Disadvantages of Palivizumab
          • Expert Insight on Palivizumab
        • Medical Practice
          • Overview
          • Respiratory Syncytial Virus Treatment Guidelines, by Market
      • Unmet Need Overview
        • Introduction
          • Key Findings
          • Expert Insight
        • Attainment of Unmet Needs
          • Current Attainment of Unmet Needs in Respiratory Syncytial Virus
          • Future Attainment of Unmet Needs in Respiratory Syncytial Virus
          • Top Unmet Needs in Respiratory Syncytial Virus—Current and Future Attainment
          • Expert Insight on Respiratory Syncytial Virus Unmet Needs
      • Emerging Therapies Overview
        • Introduction
          • Key Findings
          • Expert Insight
          • Pipeline Overview
          • Pipeline Trends in Respiratory Syncytial Virus
        • Late-Phase Pipeline Analysis
          • Notable Developments in the Late-Phase Pipeline for Respiratory Syncytial Virus
          • Therapies in Late-Phase Development for Respiratory Syncytial Virus
          • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Respiratory Syncytial Virus
        • Key Emerging Therapies
          • RSV-F Profile
          • Select Clinical Trial Results for RSV-F Vaccine for the Treatment of Respiratory Syncytial Virus
          • RSV-F Clinical Development
          • Key Ongoing Clinical Trials of the RSV-F Vaccine for the Prevention of Respiratory Syncytial Virus
          • Expert Insight
          • Expert Insight on RSV-F Vaccine
          • Expectations for Launch and Sales Opportunity of RSV-F Vaccine in Respiratory Syncytial Virus
          • REGN-2222 Profile
          • Select Clinical Trial Results for REGN-2222 for the Prevention of Respiratory Syncytial Virus
          • REGN-2222 Clinical Development
          • Key Ongoing Clinical Trials of REGN-2222 for the Prevention of Respiratory Syncytial Virus
          • Expert Insight
          • Expert Insight on REGN-2222
          • Expectations for Launch and Sales Opportunity of REGN-2222 in Respiratory Syncytial Virus
          • Antivirals' Profile
          • Select Clinical Trial Results for Antivirals in the Treatment of Respiratory Syncytial Virus
          • Antivirals' Clinical Development
          • Key Ongoing Clinical Trials of Antivirals for the Treatment of Respiratory Syncytial Virus
          • Expert Insight
          • Expert Insight on Antivirals
          • Expectations for Launch and Sales Opportunity of Antivirals in Respiratory Syncytial Virus
        • Early-Phase Pipeline Analysis
          • Notable Developments in the Early-Phase Pipeline for Respiratory Syncytial Virus
          • Select Early-Phase Compounds in Development for Respiratory Syncytial Virus
      • Access and Reimbursement Overview
        • Region-Specific Reimbursement Practices
        • Methodology
          • Appendix
            • Key Abbreviations Related to Respiratory Syncytial Virus
            • Brands, Marketers, and Generic Availability of Key Therapies for Respiratory Syncytial Virus, by Market
            • Experts Interviewed
            • Respiratory Syncytial Virus Bibliography

        Author(s): Michael Breen, PhD

        Michael is a business insights analyst on the Infectious, Niche, and Rare Diseases team. He has authored reports on cystic fibrosis, nonalcoholic steatohepatitis, vaccines, and  respiratory syncytial virus, and will author a report on cytomegalovirus. He also provides coverage for Decision Resources’ Company & Drug Insights covering anti-infectives, vaccines, and transplant therapy areas.

        Michael received his Bachelor’s degree from Hunter College with a dual major in biology and biochemistry. He received his Ph.D. in biochemistry from Boston University School of Medicine. His postdoctoral research was carried out at Brigham and Women’s Hospital/Harvard Medical School, with a focus on identifying novel pathways regulating thermogenesis in search of a therapeutic for obesity and diabetes.


        Related Reports

        Biosimilars - Market Events And Forecast - Respiratory

        In 2019, sales of branded biologics in respiratory indications reached nearly $1.6 billion in the major pharmaceutical markets under study (United States,

        View Details